ON：2025-12-08 TAGS：GLUETACS THERAPEUTICS

Gluetacs Therapeutics, an innovative clinical-stage biopharmaceutical company focused on protein degradation technology, today announced the successful enrollment of the first patient in its Phase II clinical trial of GT919. GT919 is a highly selective, self-developed oral molecular glue degrader (MGD) being evaluated for the treatment of relapsed or refractory POEMS syndrome. First-patient enrollment was completed in China on December 3, 2025  (Clinical Trial Registration Number: CTR20253208).

About POEMS 

POEMS syndrome is a rare plasma cell disorder primarily presenting with sensory and motor peripheral neuropathy, often accompanied with multi-system involvement driven by abnormal plasma cell activity. Its complex clinical presentation makes diagnosis and treatment particularly challenging. Since first being described in 1938, POEMS syndrome has remained a significant unmet medical need across hematology, neurology, and endocrinology. Currently, treatment options remain limited worldwide, and patients often face substantial long-term disease burden and reduced quality of life.

About GT919 

GT919 is an oral molecular glue degrader that induces the degradation of IKZF3/1 proteins via the CRBN-dependent pathway. Preclinical and Phase I clinical studies have demonstrated that GT919 exhibits safety and efficacy exceeding expectations. Its current advancement into development for a second indication, POEMS syndrome, marks GT919’s progression from single-indication development (R/R MM) toward expansion into multiple indications.